NDA 218860 · Ipsen
Iqirvo
Elafibranor · Oral · Peroxisome Proliferator-activated Receptor Agonist
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Jun 10, 2024: To treat primary biliary cholangitis in combination with ursodeoxycholic acid
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 10, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
6 Phase 3, 3 recruiting
FAERS reports
900
235 serious, 36 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 11, 2026.
IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). IQIRVO is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 ) Limitations of Use Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy). ( 8.7 , 12.3 ) Limitations of Use Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy) [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] .
Mechanism: Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro. However, the mechanism by which elafibranor exerts its therapeutic effects in patients with PBC is not well understood. Pharmacological activity that is potentially relevant to therapeutic effects includes inhibition of bile acid synthesis through activation of PPAR-alpha and PPAR-delta. The signaling pathway for PPAR-delta was reported to include Fibroblast Growth Factor 21 (FGF21)-dependent downregulation...
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 10, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- IQIRVO · ELAFIBRANOR 80MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elafibranor" as an intervention, any sponsor and status, largest first.
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingTerminated
GenfitIndustry
NCT02704403 · 2,157 participants · Start Mar 2016 · Primary completion Oct 28, 2020
Drug: Elafibranor; Placebo · For: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 326 sites in all
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT07387549 · 350 participants (planned) · Start May 14, 2026 · Primary completion Apr 30, 2031
Drug: Elafibranor · For: Primary Sclerosing Cholangitis
Sites: Chandler, Arizona; Phoenix, Arizona; Coronado, California · 231 sites in all
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT06016842 · 276 participants (planned) · Start Aug 31, 2023 · Primary completion May 31, 2029
Drug: Elafibranor · For: Primary Biliary Cholangitis (PBC)
Sites: Tucson, Arizona; Little Rock, Arkansas; Coronado, California · 198 sites in all
- Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
GenfitIndustry
NCT01694849 · 275 participants · Start Sep 2012 · Primary completion Feb 2015
Drug: GFT505 80mg; GFT505 120mg and 1 more · For: Non-Alcoholic Steatohepatitis (NASH)
Sites: Fresno, California; La Jolla, California; Aurora, Colorado · 56 sites in all
- Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy VolunteersPivotal-lookingCompleted
GenfitIndustry
NCT02091310 · 200 participants · Start Feb 2014 · Primary completion Dec 2014
Drug: Placebo; GFT505 and 1 more · For: Healthy Volunteers
Sites: Gières, France
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Pivotal-lookingActive, not recruiting
IpsenIndustry
NCT04526665 · 161 participants · Start Sep 24, 2020 · Primary completion Jun 1, 2023
Drug: Elafibranor 80mg; Placebo · For: Primary Biliary Cirrhosis
Sites: Chandler, Arizona; Los Angeles, California; Sacramento, California · 115 sites in all
GenfitIndustry
NCT01261494 · 97 participants · Start Dec 2010 · Primary completion Jun 2011
Drug: GFT505 80mg; Placebo · For: Type II Diabetes Mellitus
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Riga, Latvia · 28 sites in all
GenfitIndustry
NCT01474161 · 96 participants · Start Nov 2011 · Primary completion Nov 2012
Drug: GFT505 120mg - old formulation; GFT505 120mg - new formulation and 4 more · For: Type 2 Diabetes; Diabetes Mellitus, Type 2; Metabolic Diseases and 3 more
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue100
- nausea86
- pruritus83
- diarrhoea74
- product dose omission issue72
- myalgia68
- constipation65
- weight increased61
- arthralgia57
- headache44
- off label use44
- dizziness43
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2024 | 76 |
| 2025 | 400 |
| 2026 | 423 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Iqirvo (Elafibranor)
2024 spending
$9.9M
Beneficiaries
260
727 claims
Per beneficiary
$37,999
$379.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $9,879,654 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Multicenter Study
- A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM, Pares A, Kowdley KV, et al. · J Hepatol 2021 · Clinical Trial, Phase II, Multicenter Study
- Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis.
Giannini EG, Pasta A, Calabrese F, et al. · Liver Int 2025 · Systematic Review, Network Meta-Analysis
- Safety profile of elafibranor versus placebo in primary biliary cholangitis: A systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials.
Khan NA, Shahbaz H, Talha M, et al. · Medicine (Baltimore) 2026 · Systematic Review, Meta-Analysis
- Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Levy C, Abouda GF, Bilir BM, et al. · J Hepatol 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.
Malik A, Nadeem M, Malik MI · Clin J Gastroenterol 2021 · Meta-Analysis, Systematic Review
Sponsor: Ipsen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.